The findings
Melatonin earns its reputation in one place, jet lag, and a much smaller one everywhere else: pooled trials put sleep onset about seven minutes faster. The dose on shelves, 5 to 10 mg, is roughly ten times the studied range, the sleep authorities in our database advise against routine use, and years of nightly use are unstudied.
Ask whether the experts agree on melatonin and the honest answer is no, with the disagreement located precisely: not over whether it does anything, but over dose and nightly use. Melatonin has strong evidence for jet lag and a small, real effect on time to fall asleep, about seven minutes in pooled trials. Shelves sell 5 to 10 milligrams, trials support a fraction of that, and long-term safety at any dose is unstudied. This library grades melatonin B on evidence and B on worth it, and this piece is the last word this site publishes on it: after a month in which melatonin has carried a newsletter story, a debate, and this slot, the topic closes here until dated news moves it.
What the trials show
Melatonin is a hormone the brain releases at night to signal darkness. Supplements shift timing more than they sedate, and that one fact explains both where the evidence is strong and where it is thin.
The strong claim is jet lag. The Cochrane review by Herxheimer and Petrie covered 10 trials of melatonin for jet lag after air travel and found it effective for crossing time zones, with the clearest benefit on eastward travel. This is the use our record grades as strong evidence, and it is the use most buyers are not buying it for.
For ordinary trouble falling asleep, the effect is real and small. Ferracioli-Oda and colleagues meta-analyzed 19 studies with 1,683 participants in 2013 and found melatonin cut sleep onset latency by 7.06 minutes and raised total sleep time by 8.25 minutes, figures our research desk confirmed to the decimal against the paper. Seven minutes is not nothing to a person lying awake, and it is not the knockout effect the packaging implies. The clinical establishment's read is cooler still: the American Academy of Sleep Medicine recommends against melatonin for chronic insomnia, with cognitive behavioral therapy for insomnia as the first-line treatment, a position the strongest pages in our page-one teardown carry and the shelf never mentions.
Dose is where the shelf and the trials part company. The physiological doses are fractions of a milligram: Zhdanova's 2001 work found 0.3 mg restored natural nighttime levels and sleep efficiency in older adults, while 3 mg kept levels raised into daylight, and Burgess showed in 2010 that 0.5 mg shifted the body's clock as much as 3.0 mg when the timing was right. Our graded record puts the studied range for sleep onset at 0.5 to 1 mg. Products commonly sell 5 to 10 mg, and even the label cannot be trusted to say which: a 2023 analysis of melatonin gummies found 22 of 25 products inaccurately labeled. The extra milligrams buy vivid dreams and morning grogginess rather than extra benefit, because the excess is still clearing at wake time: immediate-release melatonin peaks in under an hour and is mostly cleared within four to five hours, which is also why it helps sleep onset rather than sleep maintenance.
The long-term question
Short-term use is well tolerated in trials. Long-term use has not been studied well: most trials run a few weeks to a few months, and a nightly user of several years is outside the tested record.
One large observational study now sits inside that gap. A study presented at the American Heart Association's 2025 scientific sessions followed 130,828 adults with insomnia in the TriNetX database and found that people recorded as long-term melatonin users, a year or more, had higher rates of new heart failure over five years than matched non-users, with a hazard ratio of about 1.9, hospitalization of 19 percent against 6.6 percent, and mortality of 7.8 percent against 4.3 percent. That design shows an association, not proof of cause: people who take melatonin nightly for years have worse insomnia and often worse health to begin with, and the study is a conference presentation, not a randomized trial and not peer reviewed at presentation. No trial shows melatonin harming the heart, and none clears it for years of nightly use either. Our grade is unchanged by it, and the association is a reason for a long-term nightly user to raise the question with their doctor, not a verdict.
What the experts say
Two verbatim quotes are carried below, each with its source named; the one position without a verified quote is labeled a position, and one caution comes from outside our expert library and is identified as such.
Andrew Huberman does not recommend it at all: "I personally do not recommend supplementing melatonin." His stated concerns, per our record, are that typical doses of 1 to 3 mg and above run orders of magnitude above natural levels, with effects on the reproductive axis and hormones among the risks he names.
Bryan Johnson takes it at the dose the trials support: 300 micrograms before bed, citing improved sleep onset and quality at that dose without next-day hangover effects (position, no verified quote on file). The most measured daily user in the database takes roughly a twentieth of a standard gummy.
Matthew Walker, the sleep researcher, is not among this library's tracked experts, and his caution is carried here as a labeled position from outside the database: "High doses of melatonin will block the ability of your hippocampus to form new synapses." His wider position, from the same source, is that melatonin governs sleep timing rather than generating sleep, which is why his cited meta-analysis shows onset shortened by only about four minutes. Examine.com, the independent evidence database, treats melatonin as a timing aid with its best support in jet lag and circadian shifting, which is where our record also puts its strong grade.
The split, plainly: the sleep authorities advise against routine supplementation, the most measured daily user takes a fraction of a shelf dose, and nobody in the database defends 10 mg nightly.
Our grade and rationale
Longevity Lab Report grades melatonin B on evidence and B on worth it, at $5 to $8 a month.
The B rests on a split inside one record: strong evidence for jet lag, and moderate evidence for a small sleep-onset effect. It stops short of A because the popular use, nightly help falling asleep, carries the smaller effect, and because most store doses are about ten times what the evidence supports. The worth-it B is situational, and our record says so: value for its specific occasion, jet lag first. At $5 to $8 a month the cost is not the problem; using a timing hormone nightly, at ten times the studied dose, for an effect of about seven minutes, is the problem the grade is pricing.
Safety
Short-term use is well tolerated. High doses can cause vivid dreams and morning grogginess. Long-term effects in healthy adults are not well studied. Extra caution applies for children, whose supplement doses run far above physiological levels. Talk to your doctor, especially for children or if you take other sedatives. This page is information, not medical advice.
Frequently asked questions
How much melatonin should I take? Start with the studied range: 0.5 to 1 mg for sleep onset, and lower still for shifting your clock. Higher doses are not better evidenced.
Is 10 mg of melatonin too much? On this record, yes. It is ten to twenty times the studied range, with no added onset benefit, more next-morning grogginess, and levels still raised toward daylight.
When should I take it? Thirty to sixty minutes before the sleep you are aiming at for onset; for shifting your clock across time zones, timing does more work than dose.
Can I take melatonin every night? The trials do not answer this. Short-term use is well tolerated; years of nightly use are unstudied, and the one large long-term signal is observational. That is a doctor conversation, not a label claim.
Limitations: what we do not know
We do not know whether years of nightly use are safe; no trial has run long enough to say, in either direction. We do not know whether the heart failure association reflects melatonin, worse underlying insomnia, or the health profile of long-term users. We do not know the right dose for children, and this page does not offer one. And the onset effect itself comes from trials of varying quality, mostly short. What would change the grade: a long-term randomized trial with safety endpoints.
Sources
- Herxheimer A, Petrie KJ. Melatonin for the prevention and treatment of jet lag. Cochrane Database of Systematic Reviews, 2002 (10 trials).
- Ferracioli-Oda E et al. Meta-analysis of the efficacy of melatonin in primary sleep disorders. PLoS One, 2013 (19 studies, 1,683 participants; figures confirmed against the paper by our research desk, November 11, 2026).
- Zhdanova IV et al. Melatonin treatment for age-related insomnia. Journal of Clinical Endocrinology and Metabolism, 2001 (0.3 mg against 3 mg).
- Burgess HJ et al. 2010 (0.5 mg against 3.0 mg for circadian phase shifting).
- American Academy of Sleep Medicine clinical practice guideline: recommendation against melatonin for chronic insomnia, CBT-I first-line.
- Cohen PA et al. Quantity of melatonin and CBD in melatonin gummies sold in the US. JAMA, 2023 (22 of 25 products inaccurately labeled).
- American Heart Association Scientific Sessions 2025, TriNetX observational analysis (130,828 adults with insomnia; association only, not peer reviewed at presentation).
- Longevity Lab Report melatonin record: grades, dose, and pharmacokinetics (record updated October 28, 2026).
People mentioned
Supplements mentioned
Grades are research summaries, not medical advice. Decisions about your own health belong with your clinician.